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Background. A major obstacle for successful cancer treatment often is the development of drug resistance in cancer cells
during chemotherapy. Therefore, there is an urgent need for novel drugs with improved efficacy against tumor cells and with
less toxicity on normal cells. Artesunate (ART), a powerful anti-malarial herbal compound, has been shown to inhibit growth of
various tumor cell lines in vitro and of xenografted Kaposi’s sarcoma in mice in vivo. However, the molecular mechanisms by
which ART exerts its cytotoxicity have not been elucidated. The ART-class of anti-malarial compounds is attractive due to their
activity against multidrug-resistant Plasmodium falciparum and Plasmodium vivax strains. Another salient feature of these
compounds is the lack of severe side effects in malaria patients. Methodology and Principal Findings. In this study, we used
T-cell leukemias as a model system to study the molecular mechanisms of ART-induced apoptosis. The most typical anticancer
drugs are DNA intercalators such as Doxorubicin. To investigate drug sensitivity and resistance, we chose a Doxorubicin-
resistant leukemia cell line and investigated the killing effect of ART on these cells. We show that ART induces apoptosis in
leukemic T cells mainly through the mitochondrial pathway via generation of reactive oxygen species (ROS), a mechanism
different from Doxorubicin. This is confirmed by the fact that the antioxidant N-Acetyle-Cysteine (NAC) could completely block
ROS generation and, consequently, inhibited ART-induced apoptosis. Therefore, ART can overcome the Doxorubicin-resistance
and induce the Doxorubicin-resistant leukemia cells to undergo apoptosis. We also show that ART can synergize with
Doxorubicin to enhance apoptotic cell death in leukemic T cells. This synergistic effect can be largely explained by the fact that
ART and Doxorubicin use different killing mechanisms. Conclusions. Our studies raise the possibility to develop ART in
combination with other established anticancer drugs which induce apoptosis through the pathways or mechanisms different
from ART.
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Leukemia Cells. PLoS ONE 2(8): e693. doi:10.1371/journal.pone.0000693
INTRODUCTION
Half a century after launching chemotherapy for tumor treatment
[1], antineoplastic drugs have become an indispensable part of the
armory to combat hematopoietic malignancies. Marine and
terrestrial plants are particularly suitable to find novel drugs with
anti-tumor activity. Prominent examples for the success of natural
products originally obtained from plants to fight cancer are the
Vinca alkaloids from Catharanthus roseus, the DNA topoisomerase I
inhibitor camptothecin from Camptotheca acuminata, the terpene
paclitaxel from Taxus baccata, and the lignan podophyllotoxin,
isolated from Podophyllum peltatum [2]. In fact, 69% of anti-cancer
drugs approved between 1940 and 2002 are either natural
products or developed on the basis of knowledge gained from
natural products. About L of plant-derived drugs used today in
the clinic come from traditional medicines [3,4].
Artemisinin (ARS) also known as qinhaosu, is the active principle
of the Chinese plant Artemisia annua L. (qinhao) used for more than
2000 years in Traditional Chinese Medicine (TCM) as a remedy to
treat fever and chills caused by malaria infections [5]. A program
for the discovery of new anti-malarial drugs from TCM launched
by the Chinese government in 1972 led to the identification of ARS
[6]. ARS is a sesquiterpene lactone containing an endoperoxide
bridge representing the active moiety of the molecule. ARS exert
its anti-malarial activity by generation of organic free radicals
through cleavage of the endoperoxide bridge. The radical
molecules cause macromolecular damage by alkylating and
poisoning one or several essential malarial proteins [7].
Due to the low solubility of ARS in oil and water, several
semisynthetic derivatives have been developed, including arte-
mether, arteether, artesunate (ART) and others. ART was found
to be the most potent derivative in vitro [8]. The ARS-class of anti-
malarial compounds is attractive due to their activity against
multidrug-resistant Plasmodium falciparum and Plasmodium vivax
strains [9]. Another salient feature of these compounds is the lack
of severe side effects in malaria patients [10,11]. Neurotoxicity,
however, occurs in animals after prolonged treatment with supra-
therapeutic doses [12,13].
Over the last 10 years, studies have shown that ARS and ART
also possess profound cytotoxicity against tumor cells in vitro and in
vivo [14–18]. We have previously shown that ART triggers
apoptotic cell death in various tumor cell lines in both a p53-
dependent and –independent manner [19,20]. Apoptosis involves
two main pathways: the extrinsic pathway, initiated by binding of
ligands to specific death receptors, and the intrinsic pathway,
initiated at the mitochondria [21,22]. Triggering the extrinsic
apoptosis pathway leads to the formation of the death inducing
signaling complex (DISC) containing the FAS-associated death
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Activated caspase-8 cleaves and activates the effector caspase-3,
and activated caspase-3 cleaves target ‘‘death proteins’’ such as
poly (ADP-ribose) polymerase (PARP) leading to apoptosis.
Intrinsic death stimuli directly or indirectly activate the mitochon-
drial pathway by inducing the release of cytochrome c from the
mitochondria and the formation of the apoptosome complex with
Apaf-1 and pro-caspase-9 in the cytoplasm. Caspase-9 is activated
at the apoptosome and, in turn, activates caspase-3 and cleaves
PARP [21,22]. This death pathway is largely controlled by the
pro-apoptotic (e.g. Bax, Bad, Bid and Bak) and anti-apoptotic (e.g.
Bcl-2 and Bcl-xL) Bcl-2 family proteins [21,23].
So far, the molecular mechanisms by which ART induces
apoptosis in tumor cells have not been elucidated. Therefore, the
aim of this study was to analyze the precise apoptotic pathways
induced by ART. In addition, tumors may develop resistance to
a particular drug during chemotherapy. Therefore, it would be
interesting to know, whether ART could overcome drug-resistance
of tumors and if so, by what mechanisms. To investigate these
questions we chose leukemic T cells as a model system. We show
that ART induces apoptosis via the intrinsic death pathway in all
leukemic T-cell lines tested. To investigate drug sensitivity and
resistance, we chose a Doxorubicin-resistant cell line and showed
that ART induced apoptotic cell death in these cells. Our study
demonstrated that ART induces apoptosis through a mechanism
different from Doxorubicin and, thus, overcomes the drug-
resistance of the tumor cells. Furthermore, we show that ART
synergistically enhances Doxorubicin-induced apoptosis due to
using different killing mechanisms.
MATERIALS AND METHODS
Cell lines and culture
The human acute T cell leukemia Jurkat cell line J16, the human
acute lymphoblastic leukemia cell lines CEM and Molt-4, the
human T cell lymphoma Hut78, the genetically engineered cell
lines J-Neo, J-Bcl-2, J-caspase-8
2/2, Jurkat A3 FADD
2/2 and the
parental Jurkat A3 were cultured in RPMI 1640 medium (GIBCO
laboratories, Grand Island, NY) supplemented with 10% FCS,
50 mg/ml Gentamicin (GIBCO), 10 mM HEPES (GIBCO, 1 M
solution), and 2 mM L-glutamine (GIBCO, 200 mM solution) at
37uC and 5% CO2. All cell lines were purchased from American
Type Culture Collection (ATCC, Manassas, USA). Generation of
the Doxorubicin-resistant cell line CEM-DoxR (CCRF-CEM/
ADR5000) was described previously [24]. The multi-drug re-
sistance phenotype of this cell line has been described previously
[19,25].
Determination of apoptosis
Cells were plated in triplicates and treated for the indicated
periods of time at 37uC with different drugs. The pan-caspase
inhibitor zVAD-fmk was purchased from Bachem (Weil am
Rhein, Germany). Apoptotic cell death was examined by two
parameters: FSC/SSC index of apoptotic-like change in cell size
and granularity by FACScan and by analysis of DNA fragmen-
tation according to the method of Nicoletti [26]. Briefly, cells were
resuspended in a buffer containing 0.1% (w/v) sodium citrate,
0.1% (v/v) Triton X-100 and 50 mg/ml propidium iodide (Sigma).
After incubation at 4uC in the dark for at least 16 h apoptotic
nuclei were quantified by FACScan (Becton Dickinson).
Western blot analysis
1610
6 cells were sedimented and lysed for 15 min in ice-cold lyses
buffer (15 mM Tris-HCl, pH 7.4, 137 mM NaCl, 10% (w/v)
Glycerin, 1% (v/v) Triton X-100, 2 mM EDTA, 1 mM PMSF,
0.4 mM Na3VO4, 10 mM NaF, complete protease inhibitor
cocktail, Roche). After removing the cell debris by centrifugation
at 13,000 rpm for 15 min, equal amounts of proteins were
seperated on a 12% SDS-PAGE under reducing conditions,
blotted onto a nitrocellulose membrane (Amersham Biosciences,
Little Chalfon, UK) and blocked with 5% non-fat drymilk in
PBS/Tween (0.05% Tween-20 in PBS). The following antibodies
were used: caspase-2 mAb (mouse IgG1, Cell Signaling, Ger-
many), Cytochrome c (Cell Signaling), caspase-9 mAb (Santa Cruz
Biotechnology, Santa Cruz, CA), caspase-3 polyclonal antibody
(Cell Signalling), caspase-8 mAb C15 (mouse IgG2b) recognizes
the p18 subunit of caspase-8 (made in our lab) [27], PARP [poly
(ADP-ribose) polymerase] mAb (BD PharMingen, Germany) and
tubulin (Sigma, Taufkirchen, Germany). Enhanced chemilumi-
nescence (PerkinElmer Life Sciences, Boston, MA) was used for
detection. For stripping, blots were incubated for 30 min in
a buffer containing 62.5 mM Tris/HCl, pH 6.8, 2% SDS, and
100 mM b-mercaptoethanol at 56uC. The blots were washed six
times for 10 min in PBS/Tween and blocked again in 5% non-fat
drymilk.
Redox measurement
Doxorubicin (500 ng/ml) or ART (2–4 mg/ml) treated cells were
stained for 30 min with 5 mM of the H2O2-sensitive fluoresent dye
dichlorofluorescein diacetate (DCFDA, FL-1) (Molecular Probes,
Inc., Eugene, OR) at 37uC in the dark, washed 3 times with PBS
and subsequently assayed by FACScan.
RESULTS
ART induces apoptosis in leukemic T cells
To investigate the cytotoxicity of ART in T cell leukemias, four
different leukemic T cell lines CCRF-CEM, Jurkat, Hut-78, and
Molt-4 were subjected to ART treatment. Apoptotic cell death was
examined by two parameters: FSC/SSC index of apoptotic-like
changes in cell size and granularity (Fig. 1A), and DNA
fragmentation (Fig. 1B). Treatment with ART resulted in a dose-
dependent induction of apoptotic cell death in all malignant T cell
lines tested. The minimum ART concentration to induce 30–50%
of Jurkat, Hut-78 and Molt-4 cells to undergo apoptosis in 48 h
was about 2, 6 and 0.5 mg/ml, respectively. The cytotoxic effect of
ART on CCRF-CEM cells was even stronger. The minimum
concentration of ART to induce 30–50% apoptosis in CEM cells
in 24 h was about 0.1 mg/ml. The data demonstrate that ART
can induce substantial and variable apoptotic cell death in
different leukemic cells.
ART induces apoptosis through the intrinsic
pathway
Since apoptotic cell death may be triggered through the extrinsic
(receptor-mediated) or the intrinsic (mitochondria-mediated)
pathway, we asked which death pathway was involved in
ART-induced cell death. To investigate this question, Jurkat T
cells deficient of either the death adapter molecule FADD
(J-FADD
2/2) or caspase-8 (J-casp-8
2/2) were treated with
different concentrations of ART. The experiment showed that
both J-FADD
2/2 and J-casp-8
2/2 cells were at least as sensitive
to ART as the parental J-A3 cells indicating that the extrinsic
pathway was not involved in ART-mediated apoptosis (Fig. 2A).
This assumption was supported by a further experiment showing
that Jurkat T cells stably expressing the anti-apoptotic protein Bcl-
2 (J-Bcl-2) were significantly resistant to ART-induced apoptosis
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broad caspase inhibitor zVAD demonstrating that caspases were
involved in the death process (Fig. 2B). Kinetic analysis of proteins
involved in the apoptotic signaling pathway showed that ART did
not induce activation of caspase-8, the main caspase of the
extrinsic pathway (Fig. 2C). Instead, release of cytochrome c and
activation of caspase-9, the main caspase involved in the intrinsic
pathway, were observed upon ART treatment (Fig. 2C). ART
treatment also induced activation of caspase-2 (Fig. 2C). These
data demonstrate that ART induces apoptosis through the
intrinsic pathway.
ART-induces apoptosis by generation of ROS
The intrinsic pathway can be triggered by many stimuli including
ROS. Mitochondria are the major site of ROS production, and
accumulation of ROS may lead to the initiation of apoptosis [28].
Several studies imply that inhibition of apoptosis by Bcl-2 is
associated with protection against ROS [29,30]. ARS has been
shown to exert its anti-malarial activity by generation of organic
free radicals through cleavage of the endoperoxide bridges [7]. To
investigate whether ART killed tumor cells by inducing generation
of ROS, we monitored the redox status using the oxidation-
sensitive fluorescent dye, DCFDA, in Jurkat and CEM T cells. We
found that ART induced a rapid accumulation of H2O2 (as early
as 15 min) in Jurkat T cells which were completely blocked by the
anti-oxidant N-Acetyle-Cysteine (NAC) (Fig. 3A). Similar results
were observed in CEM cells (Fig. 3B). To further investigate
whether ART-induced ROS is required for induction of apoptosis,
Jurkat and CEM T cells were treated with ART in the presence or
absence of NAC. The experiments showed that NAC almost
completely blocked ART-induced apoptosis demonstrating that
ROS production is the cause of ART-mediated apoptotic cell
death in leukemic T cells (Fig. 3C and D).
ART induces Doxorubicin-resistant leukemic T cell to
undergo apoptosis
One of the main problems of present chemotherapy is the
development of resistance of tumor cells towards drug-induced
apoptosis. Therefore, there is a quest for the improvement of
anticancer drugs. The most typical anticancer drugs are DNA
intercalators such as Doxorubicin. To investigate whether ART
could overcome such resistance, a Doxorubicin-resistant CEM
sub-cell line CEM/ADR5000 [24] was treated with ART. As
shown in Fig. 4A, CEM/ADR5000 (CEM-DoxR) cells were
resistant whereas the parental cells CCRF-CEM (CEM-parental)
were sensitive to Doxorubicin treatment. The experiment showed
Figure 1. ART induces apoptosis in malignant T cells. Jurkat, Hut-78, Molt-4 and CEM leukemic T cells were incubated with different doses of ART for
24 or 48 h as indicated. The apoptotic cell death was determined either by FSC/SSC index for changes in cell size and granularity (A) or by DNA
fragmentation (B). Results are representative of three independent experiments determined in triplicates.
doi:10.1371/journal.pone.0000693.g001
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determined by both FSC/SSC (Fig. 4A, left panel) and DNA
fragmentation (Fig. 4A, right panel). Similar to other leukemic
T cells, ART-induced apoptosis of CEM-Doxr cells could be
blocked by NAC (Fig. 4B). In contrast, NAC could not block
Doxorubicin-induced apoptosis in CEM (Fig. 4C) and Jurkat T
cells (Fig. 4D). Further investigation of the ROS status after ART
or Doxorubicin treatment revealed that accumulation of ROS was
observed in ART treated CEM-DoxR cells and the ART-induced
ROS production was blocked by NAC (Fig. 4E). In contrast,
Doxorubicin at the doses that induce apoptosis in CEM and Jurkat
T cells did not show induction of ROS production (Fig. 4F). The
absence of ROS production in Doxorubicin treated cells is not due
to the intrinsic fluorescence of Doxorubicin that interferes with the
assay for ROS. As shown in Fig. 4G, equal levels of ROS were
detected when cells were treated with ART in the absence or
presence of Doxorubicin. Thus, ROS is not involved in
Doxorubicin-induced apoptosis in these cells and ROS is not
involved in Doxorubicin-induced apoptosis in these cells.
ART synergizes with Doxorubicin to enhance
apoptosis
Since ART induces apoptosis by a mechanism different from that
of Doxorubicin, we speculated that ART may cooperate with
Doxorubicin to increase killing of tumor cells. To address this,
Jurkat and CEM cells were treated with a combination of ART
and Doxorubicin at different doses. Consistently, treatment of
Jurkat and CEM cells with either ART or Doxorubicin alone
resulted in apoptotic cell death in a dose dependent manner. As
expected, treatment of these cells with a combination of ART and
Doxorubicin led to a synergistic (not only additive) increase in
apoptotic cell death. As shown in Fig. 5A, treatment of Jurkat cells
with 25 or 50 ng/ml of Doxorubicin or 2 or 4 mg/ml of ART
Figure 2. ART induces apoptosis through the intrinsic (mitochondria) pathway. (A) The death receptor system is not required for ART-induced
apoptosis. Jurkat cells deficient in FADD (FADD
2/2), caspas-8 (casp-8
2/2), or over-expressing Bcl-2 and parental (A3) Jurkat cells were treated with
different does of ART. Apoptotic cell death was determined by FSC/SSC in triplicates. (B) ART-induced apoptosis involves caspases. Jurkat cells were
treated with ART (4 mg/ml) in the presence or absence of 50 mM of pan-caspase inhibitor zVAD-fmk for 48 h. Apoptotic cell death was determined by
DNA fragmentation in triplicates. (C) ART induces cytochrome c release and activation of caspase-2, 3 and 9. CEM leukemia cells were treated with
1 mg/ml ART for different times as indicated. Cell lysates were subjected to Western blotting with antibodies against cytochrome c, caspase-2, 3, 8, 9,
PARP, and control antibodies against tubulin. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0000693.g002
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respectively, whereas, a combination of both drugs resulted in 44
to 87% apoptosis. The synergistic effect of the two drugs was even
more significant when the drugs were given to CEM cells. As
shown in Fig. 5B, treatment of CEM cells with ART or
Doxorubicin alone led to only 7 to 13% and 3 to 4% apoptosis,
respectively. However, a combination of both drugs resulted in
more than 60% apoptotic cell death. Thus, ART can synergize
with Doxorubicin to enhance the efficacy of killing of tumor cells.
DISCUSSION
We have previously shown that ART inhibits angiogenesis in mice
xenografted with Kaposi’s sarcoma [14] and trigger apoptotic cell
death in various tumor cell lines in vitro [19,20]. Although the
cytotoxicity of ART for tumor cells was found a decade ago [15],
the molecular mechanisms by which ART exerts its anti-tumor
activity have not been elucidated. In this study, using leukemic T
cells as a model system, we show that ART induces malignant T
cells to undergo apoptosis through the mitochondria pathway.
This is demonstrated by inducing the release of cytochrome c from
the mitochondria upon ART treatment and followed by activation
of caspase-9, the main caspase involved in the intrinsic pathway.
In contrast, no activation of caspase-8, the main caspase for the
extrinsic pathway, was seen. Furthermore, cells deficient of either
the death adapter molecule FADD or caspase-8 were at least as
sensitive to ART as the parental cells. Further investigation of the
molecular mechanisms by which ART triggers apoptosis revealed
that ART induces the intrinsic death pathway by generation of
ROS. This is confirmed by the fact that the antioxidant NAC
could completely block ROS generation and, consequently,
inhibited ART-induced apoptosis.
Resistance to apoptosis may be a key factor of tumor cell survival.
A major obstacle for successful cancer treatment often is the
development of drug resistance in cancer cells. Therefore, there is an
urgent need for novel drugs with improved efficacy against tumor
cells and with less toxicity on normal cells. ART shows efficacy
against multidrug-resistant Plasmodium strains and is surprisingly well
tolerated [9,11]. Thus, ART may be a candidate for use in cancer
therapy. As an example, we demonstrate here that ART can
overcome apoptosis resistance of Doxorubicin in a resistant cell line.
The anticancer drug Doxorubicin (Adriamycin) belongs to the
anthracycline-based DNA intercalators. It is well accepted that the
anticancer activity of Doxorubicin is caused by inhibition of DNA
polymerases, DNA topoisomerase II, and DNA methyltransferase,
resulting in induction of apoptosis [31–33]. We show that ART
induces apoptosis in leukemic T cells via generation of ROS,
a mechanism different from Doxorubicin. Therefore, ART can
induce the Doxorubicin-resistant CEM cells to undergo apoptosis.
Figure 3. ROS mediate ART-induced apoptosis in leukemia cells. (A) Jurkat cells were treated with 4 mg/ml of ART for different times as indicated
and the redox status was monitored by the oxidation-sensitive fluorescent dyes for H2O2. (B) CEM cells were treated with 0.5 mg/ml doses ART. After
30 min, the redox status was measured as in (A). (C) and (D) ART-induced apoptosis was blocked by the antioxidant NAC. Jurkat (C) and CEM (D) cells
were treated with ART in the presence (15 mM) or absence of NAC for 24 h. Apoptotic cell death was analyzed by FSC/SSC in triplicates. Results are
representative of four independent experiments.
doi:10.1371/journal.pone.0000693.g003
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Doxorubicin. (A) ART induces apoptosis in Doxorubicin-resistant leukemic cells. Doxorubicin-resistant (CEM-DoxR) and parental (CEM-parental) CEM
cells were treated with either 1 mg/ml of ART or 0.5 mg/ml of Doxorubicin for 24 h. Apoptosis was determined by FSC/SSC (left panel) and DNA
fragmentation (right panel). Results are representative of two independent experiments. (B) NAC inhibits ART-induced apoptosis in Doxorubicin-
resistant leukemic cells. CEM-DoxR cells were treated with different doses of ART in the presence or absence of NAC (15 mM). Apoptotic cell death
was determined by DNA fragmentation in triplicates. (C) and (D) NAC does not inhibit Doxorubicin-induced apoptosis. CEM-parental (C) and Jurkat
(D) cells were treated either with ART or Doxorubicin in the presence or absence of NAC. Apoptotic cell death was determined by DNA fragmentation.
Results are representative of four independent experiments. The p value was determined by the statistic program of Microsoft Excel. (E) ART induces
ROS generation in CEM-DoxR cells. CEM-DoxR cells were treated with 4 mg/ml of ART in the presence or absence of NAC (15 mM) for 30 min. The
redox status was measured as in figure 3. (F) Doxorubicin does not induce ROS in leukemic T cells. CEM-DoxR, CEM-parental and Jurkat cells were
treated with 0.5 mg/ml of Doxorubicin in the presence or absence of NAC for 30 min. The redox status was measured as in (E). Results are
representative of three independent experiments. (G) Doxorubicin does not interfere with the redox assay. CEM cells were treated with Doxorubicin
(2 mg/ml) or ART (4 mg/ml) alone or in combination for 30 min. The redox status was measured as in F.
doi:10.1371/journal.pone.0000693.g004
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lymphoblasticleukemiacelllinesCEMandMolt-4 wereshowntobe
approximately 5- to10-fold more susceptible to ART treatment than
the acute leukemia T cell line Jurkat and the T lymphoma cell line
Hut78. Such difference might be due to different expression levels of
anti- or/and pro-apoptotic proteins in different types of tumors. In
addition, different types of tumors may express different amounts of
multi-drug transporter proteins on their plasma membrane which
may also account for such differences.
Besides the DNA intercalating function, Doxorubicin has been
also proposed to induce oxidative stress in colon tumor cells [34]
and cardiac cells [35]. However, we did not detect any ROS
generation by Doxorubicin at the doses that induce apoptosis in
leukemic T cells. Also, in all leukemic T cell lines tested the
Doxorubicin-induced apoptosis could not be blocked by the
antioxidant NAC indicating that ROS is not the cause of
Doxorubicin-induced apoptotic cell death in these cells. Our
result is supported by an early study showing that a low dose of
Doxorubicin, at which it could induce ROS generation in Jurkat T
cells, led to necrosis, whereas a high dose of Doxorubicin causes
apoptosis but no ROS generation [36].
It has been reported that ART and Doxorubicin had synergistic
effects on killing of Plasmodium falciparum, although the mechanistic
aspects have not been addressed [37]. Interestingly, we also found
that ART can synergize with Doxorubicin to enhance apoptotic
cell death in leukemic T cells. This synergistic effect can be largely
explained by the fact that ART and Doxorubicin use different
killing mechanisms. DNA intercalating agents, such as Amsacrine,
Actinomycin, Mitoxantrone, and Doxorubicin, have been em-
ployed as anticancer drugs and are routinely used in the clinic as
chemotherapeutic agents [38]. We assume that ART may also
cooperate with other DNA intercalating anticancer drugs under
the same principle. Thus, our studies raise the possibility to
develop ART in combination with other established anticancer
drugs which induce apoptosis through the pathways or mech-
anisms different from ART.
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